ReviewCurrent opinion in critical care2016
Anabolic and anticatabolic agents in critical care.
Review in Current opinion in critical care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06592144 (TESTO-TRIAL), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TESTO-TRIAL: Randomized Clinical Trial on the Use of Testosterone in Critically Ill Patients
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Why does COVID-19 kill more elderly men than women? Is there a role for testosterone?Andrology · 2021Pooled it
- Novel Strategies to Promote Intensive Care Unit Recovery via Personalized Exercise, Nutrition, and Anabolic Interventions.Critical care clinics · 2025Review
- Metformin is associated with reduced risk of mortality and morbidity in burn patients compared to insulin.Burns : journal of the International Society for Burn Injuries · 2024Article
- Post-intensive care syndrome follow-up system after hospital discharge: a narrative review.Journal of intensive care · 2024Review
- Personalized nutrition therapy in critical care: 10 expert recommendations.Critical care (London, England) · 2023Review
- The Good, the Bad, and the Serum Creatinine: Exploring the Effect of Muscle Mass and Nutrition.Blood purification · 2023Review
- Exercise Limitation after Critical Versus Mild COVID-19 Infection: A Metabolic Perspective.Journal of clinical medicine · 2022Article
- Postacute Sequelae of COVID-19 Critical Illness.Critical care clinics · 2022Review
- Prevalence of nutritional risk and malnutrition during and after hospitalization for COVID-19 infection: Preliminary results of a single-centre experience.Clinical nutrition ESPEN · 2021Article
- Cardiopulmonary Exercise Testing in Critically Ill Coronavirus Disease 2019 Survivors: Evidence of a Sustained Exercise Intolerance and Hypermetabolism.Critical care explorations · 2021Article
- Article
- Glucose Metabolism in Burns-What Happens?International journal of molecular sciences · 2021Review
- Role of anabolic testosterone agents and structured exercise to promote recovery in ICU survivors.Current opinion in critical care · 2020Review
- The association between the route of nutrition and serum levels of adipokines in critical illness: a pilot studyTurkish journal of medical sciences · 2020Article
- Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.Burns : journal of the International Society for Burn Injuries · 2020Review
- The Safety and Effect of Early Mobilization in the Intensive Care Unit According to Cancellation Criteria.Progress in rehabilitation medicine · 2020Article
- Nutrition therapy and critical illness: practical guidance for the ICU, post-ICU, and long-term convalescence phases.Critical care (London, England) · 2019Review
- Post-intensive care syndrome: its pathophysiology, prevention, and future directions.Acute medicine & surgery · 2019Review
- Nutrition Therapy in Sepsis.Critical care clinics · 2018Review
- Tailoring nutrition therapy to illness and recovery.Critical care (London, England) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
purpose of reviewA complex network of hormones and other effectors characterize the hypermetabolic response in critical illness; these mediators work together to induce numerous pathophysiologic alterations. Increased incidence of infection, multiorgan failure, long-term debilitation, delays in rehabilitation, and death result from an inability to meet the prohibitively elevated protein and energy requirements, which occur during illness and can persist for several years. Pharmacologic interventions have been successfully utilized to attenuate particular aspects of the hypermetabolic response; these modalities are a component of managing critically ill patients - including those patients with severe burns. Here, we review recent advances in pharmacologically attenuating the hypermetabolic and catabolic responses. RECENT
findingsPropranolol, a nonspecific β-adrenergic receptor antagonist, is one of the most widely used anticatabolic therapies. Oxandrolone, testosterone, and intensive insulin therapy represent anabolic pharmacological strategies. Promising therapies, such as metformin, glucagon-like peptide 1, peroxisome proliferator-activated receptor agonists, are currently being investigated. SUMMARY: Profound metabolic derangements occur in critically ill patients; this hypermetabolic response is a major contributor to adverse outcomes. Despite the pharmacological therapies currently available to counteract this devastating cascade, future studies are warranted to explore new multimodality agents that will counteract these effects while maintaining glycemic control and preventing unfavorable complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.